Scientific literature addressing brain glioma in the web of science: A 10-year bibliometric analysis

Neural Regeneration Research

Volumn 6, Issue 32, 2011, Pages 2537-2544

  Xu, Zaihua ^a   Tang, Tao ^a   Pan, Dongsheng ^a   Fan, Di ^a   Song, Zhenquan ^a   Xue, Hongli ^a  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

Analysis; Bibliometrics; Brain glioma; SCI; Scientific literature

Indexed keywords

ARTICLE; BIBLIOMETRICS; CANCER RESEARCH; CITATION ANALYSIS; FUNDING; GLIOMA; MEDICAL LITERATURE; PUBLICATION; SCISEARCH; TREND STUDY;

EID: 82555172980     PISSN: 16735374     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Markert JM, Parker JN, Gillespie GY, et al. Genetically engineered human herpes simplex virus in the treatment of brain tumours. Herpes. 2001;8(1):17-22.
2. Occhiogrosso G, Edgar MA, Sandberg DI, et al. Prolonged convection-enhanced delivery into the rat brainstem. Neurosurgery. 2003;52(2):388-393.
3. Hang CH. Treatment process of brain glioma. Zhongguo Weiqinxi Shenjing Waike Zazhi. 2011;16(9):429-432.
4. Almind TC, Ingwersen P. Informetric analyses on the World Wide Web: methodological approaches to "webometrics. J Doc. 1997;53(4):404-426.
5. Campanario JM, González L, Rodríguez C. Structure of the impact factor of academic journals in the field of Education and Educational Psychology: citations from editorial board members. Scientometrics. 2006;69(1):37-56.
6. Moed HF, Burger WJM, Frankfort JG, Vanraan AFJ. The use of bibliometric data for the measurement of university research performance. Res Policy. 1985;14(3):131-149.
7. Schubert A, Glänzel W, Braun T. Scientometric datafiles: a comprehensive set of indicators on 2649 journals and 96 countries in all major science fields and subfields 1981-1985. Scientometrics. 1989;16(1-6):3-478.
8. Vergidis PI, Karavasiou AI, Paraschakis K, et al. Bibliometric analysis of global trends for research productivity in microbiology. Eur J Clin Microbiol Infect Dis. 2005;24:342-345.
9. Falagas ME, Karavasiou AI, Bliziotis IA. A bibliometric analysis of global trends of research productivity in tropical medicine. Acta Trop. 2006;99:155-159.
10. Kumari L. Trends in synthetic organic chemistry research. Cross-country comparison of activity index. Scientometrics. 2006;67:467-476.
11. Garfield E, Welljamsdorof A. The microbiology literature: languages of publication and their relative citation impact. FEMS Microbiol Lett. 1992;100:33-37.
12. Hsieh WH, Chiu WT, Lee YS, et al. Bibliometric analysis of patent ductus arteriosus treatments. Scientometrics 2004;60:205-215.
13. Chen SR, Chiu WT, Ho YS. Asthma in children: mapping the literature by bibliometric analysis. Rev Fr Allergol Immunol Clin. 2005;45:442-446.
14. Chiu WT, Ho YS. Bibliometric analysis of tsunami research. Scientometrics. 2007;73:3-17.
15. Li T, Ho YS, Li CY. Bibliometric analysis on global Parkinson's disease research trends during 1991-2006. Neurosci Lett. 2008;441(3):248-252.
16. Zhou JY, Sun T. A Quantitative analysis of digital library research article based on the Web of Science. Qingbao Kexue. 2005;23(10):1521-1525.
17. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
18. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756-760.
19. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64(19):7011-7021.
20. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359(9311):1011-1018.
21. Fulda S, Wick W, Weller M, et al. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med. 2002;8(8): 808-815.
22. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3):157-173.
23. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006;9(5):391-403.
24. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25(30):4722-4729.
25. De Palma M, Venneri MA, Galli R, et al. Tie2 identifies a hematopoietic monocytes required for tumor lineage of proangiogenic vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell. 2005;8(3):211-226.
26. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5(2):79-88.
27. Vredenburgh JJ, Desjardins A, Herndon II JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13(4):1253-1259.
28. Patrawala L, Calhoun T, Schneider-Broussard R, et al. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res. 2005; 65(14): 6207-6219.
29. Ignatova TN, Kukekov VG, Laywell ED, et al. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia. 2002;39(3):193-206.
30. Nakamizo A, Marini F, Amano T, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 2005;65(8):3307-3318.
31. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006;66(16):7843-7848.
32. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis. Clin Cancer Res. 2001;7(4):839-845.
33. Dai C, Celestino JC, Okada Y, et al. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev. 2001;15(15): 1913-1925.
34. Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 2007;318(5848):287-290.
35. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol. 2003;24(10):1989-1998.
36. Clement V, Sanchez P, de Tribolet N, et al. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol. 2007;17(2):165-172.
37. Deng W, Obrocka M, Fischer I, et al. In vitro differentiation of human marrow stromal cells into early progenitors of neural cells by conditions that increase intracellular cyclic AMP. Biochem Biophys Res Commun. 2001;282(1):148-152.
38. Veiseh O, Sun C, Gunn J, et al. Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Lett. 2005;5(6):1003-1008.
39. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst. 2005;97(12):880-887.
40. Inskip PD, Tarone RE, Hatch EE, et al. Cellular-telephone use and brain tumors. N Engl J Med. 2001;344(2):79-86.
41. Kircher MF, Mahmood U, King RS, et al. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res. 2003;63(23):8122-8125.
42. Joki T, Machluf M, Atala A, et al. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotechnol. 2001;19(1):35-39.
43. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. 2001;61(18):6624-6628.
44. Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg. 2001;95(5):735-745.
45. Skog J, Würdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10(12): 1470-1476.
46. Moffat BA, Chenevert TL, Lawrence TS, et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A. 2005;102(15):5524-5529.
47. Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol. 2001;19(2):509-518.
48. Zhou Y, Larsen PH, Hao C, et al. CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem. 2002;277(51):49481-49487.
49. Laws ER, Parney IF, Huang W, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg. 2003;99(3): 467-473.
50. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20(8):2076-2084.
51. Karim AB, Afra D, Cornu P, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys. 2002;52(2): 316-324.
52. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.
53. Shoshani T, Faerman A, Mett I, et al. Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol Cell Biol. 2002;22(7):2283-2293.
54. Nakamura K, Ito Y, Kawano Y, et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther. 2004;11(14):1155-1164.
55. Yu JS, Liu G, Ying H, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004;64(14):4973-4979.
56. Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009;324(5924):261-265.
57. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003;63(20):6962-6970.
58. Lokker NA, Sullivan CM, Hollenbach SJ, et al. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res. 2002;62(13):3729-2735.
59. Rola R, Raber J, Rizk A, et al. Radiation-induced impairment of hippocampal neurogenesis is associated with cognitive deficits in young mice. Exp Neurol. 2004;188(2):316-330.
60. Jackson EL, Garcia-Verdugo JM, Gil-Perotin S, et al. PDGFR alpha-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling. Neuron. 2006;51(2):187-199.
61. Wiendl H, Mitsdoerffer M, Hofmeister V, et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol. 2002;168(9):4772-4780.
62. Qiu JP, Wang HX. The level analysis of bibliometrics development in the 20th century. Gaoxiao Tushuguan Gongzuo. 2000;20(80): 130.